Takip et
Eduard Porta-Pardo
Eduard Porta-Pardo
Josep Carreras Leukaemia Research Institute
bsc.es üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
50082018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
24312018
The functional impact of alternative splicing in cancer
H Climente-González, E Porta-Pardo, A Godzik, E Eyras
Cell reports 20 (9), 2215-2226, 2017
5612017
A structural biology community assessment of AlphaFold 2 applications
M Akdel, DEV Pires, EP Pardo, J Jänes, AO Zalevsky, B Mészáros, ...
Nature Structural and Molecular Biology 29, 1056-1067, 2022
5012022
Perspective on oncogenic processes at the end of the beginning of cancer genomics
L Ding, MH Bailey, E Porta-Pardo, V Thorsson, A Colaprico, D Bertrand, ...
Cell 173 (2), 305-320. e10, 2018
4002018
A pan-cancer catalogue of cancer driver protein interaction interfaces
E Porta-Pardo, L Garcia-Alonso, T Hrabe, J Dopazo, A Godzik
PLoS computational biology 11 (10), e1004518, 2015
1472015
e-Driver: a novel method to identify protein regions driving cancer
E Porta-Pardo, A Godzik
Bioinformatics 30 (21), 3109-3114, 2014
1442014
Germline genetic contribution to the immune landscape of cancer
RW Sayaman, M Saad, V Thorsson, D Hu, W Hendrickx, J Roelands, ...
Immunity 54 (2), 367-386. e8, 2021
1422021
Autoimmune predisposition in Down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens
M Giménez-Barcons, A Casteras, MP Armengol, E Porta, PA Correa, ...
The Journal of Immunology 193 (8), 3872-3879, 2014
1252014
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
L De Mattos-Arruda, M Vazquez, F Finotello, R Lepore, E Porta, J Hundal, ...
Annals of oncology 31 (8), 978-990, 2020
1202020
The structural coverage of the human proteome before and after AlphaFold
E Porta-Pardo, V Ruiz-Serra, S Valentini, A Valencia
PLoS computational biology 18 (1), e1009818, 2022
1042022
Comparison of algorithms for the detection of cancer drivers at subgene resolution.
E Porta-Pardo, A Kamburov, D Tamborero, T Pons, D Grases, A Valencia, ...
Nature Methods, 2017
872017
Epigenetic regulation during cancer transitions across 11 tumour types
NV Terekhanova, A Karpova, WW Liang, A Strzalkowski, S Chen, Y Li, ...
Nature 623 (7986), 432-441, 2023
672023
Cancer3D: understanding cancer mutations through protein structures
E Porta-Pardo, T Hrabe, A Godzik
Nucleic Acids Research, 2014
572014
Pan-cancer proteogenomics connects oncogenic drivers to functional states
Y Li, E Porta-Pardo, C Tokheim, MH Bailey, TM Yaron, V Stathias, ...
Cell 186 (18), 3921-3944. e25, 2023
492023
Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
E Porta‐Pardo, A Valencia, A Godzik
FEBS letters 594 (24), 4233-4246, 2020
452020
Mutation Drivers of Immunological Responses to Cancer
E Porta-Pardo, A Godzik
Cancer immunology research 4 (9), 789-798, 2016
402016
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
WW Liang, RJH Lu, RG Jayasinghe, SM Foltz, E Porta-Pardo, Y Geffen, ...
Cancer cell 41 (9), 1567-1585. e7, 2023
392023
AIRE genetic variants and predisposition to polygenic autoimmune disease: The case of Graves’ disease and a systematic literature review
R Colobran, M Giménez-Barcons, A Marín-Sánchez, E Porta-Pardo, ...
Human Immunology 77 (8), 643-651, 2016
252016
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools
C Garcia-Prieto, F Martínez-Jiménez, A Valencia, E Porta-Pardo
Bioinformatics, 2022
18*2022
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20